<DOC>
	<DOCNO>NCT00372723</DOCNO>
	<brief_summary>To determine whether treatment patient toxic epidermal necrolysis drug call remicaide increase number patient alive 30 day laters .</brief_summary>
	<brief_title>Study Potential New Treatment Patients With Toxic Epidermal Necrolysis ( TEN )</brief_title>
	<detailed_description>This pilot ( preliminary ) study . Patients diagnosis TEN ask consider participate . The study intervention single intravenous dose remicaide ( 5 mg/kg ) . Standard supportive care give . The percentage patient alive 30 day treatment remicaide compare historical control .</detailed_description>
	<mesh_term>Stevens-Johnson Syndrome</mesh_term>
	<mesh_term>Infliximab</mesh_term>
	<criteria>Admission burn unit histologic diagnosis TENs Pregnancy hypersensitivity remicaide history heart failure document bacteremia history cancer inability consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>toxic epidermal necrlysis</keyword>
	<keyword>ten</keyword>
</DOC>